Wilfried Eberhardt

38.9k citations
243 papers · 7.9k · 4 hit papers · h-index 40

Impact in

    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment
    • Occupational and environmental lung diseases
  • Oncology top 0.5%
    • Lung Cancer Research Studies
    • Colorectal Cancer Treatments and Studies
    • Cancer Immunotherapy and Biomarkers
    • HER2/EGFR in Cancer Research

Papers in

    • Lung Cancer Treatments and Mutations 110
    • Lung Cancer Diagnosis and Treatment 71
    • Lung Cancer Research Studies 46
    • Cancer Immunotherapy and Biomarkers 17
    • Colorectal Cancer Treatments and Studies 16
    • Cancer Treatment and Pharmacology 15

Wilfried Eberhardt

226 papers receiving 7.7k citations

Wilfried Eberhardt's Hit Papers

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial 2015 · 294 citations
2940+5+11Years since publication2505007501000

Peers

Wilfried Eberhardt
Comparison fields: 5 of 124
  • Pulmonary and Respiratory Medicine 4.5k
  • Oncology 3.1k
  • Cancer Research 709
  • Radiology, Nuclear Medicine and Imaging 590
  • Otorhinolaryngology 94
Replace Philip Bonomi with:
Philip Bonomi United States
Thomas E. Stinchcombe United States
Christopher G. Azzoli United States
Élisabeth Quoix France
Bartomeu Massutí Spain
Daniel Castellano Spain
Rogério Lilenbaum United States
Masahiko Higashiyama Japan
Renato Martins United States
Charles Butts Canada
Wilfried Eberhardt relative to Philip Bonomi United States Philip Bonomi's profile →
Citations per field
00.5×1.5×1.9×
Philip Bonomi · 1×
Citations per year

Countries citing papers authored by Wilfried Eberhardt

Since Specialization
Citations

This map shows the geographic impact of Wilfried Eberhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wilfried Eberhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wilfried Eberhardt more than expected).

Fields of papers citing papers by Wilfried Eberhardt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wilfried Eberhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wilfried Eberhardt. The network helps show where Wilfried Eberhardt may publish in the future.

Co-authors

The 25 scholars most cited alongside Wilfried Eberhardt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Wilfried Eberhardt Line = papers co-authored together Wilfried Eberhardt links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 243 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Hit paper breakdown →
20091078
2
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
Hit paper breakdown →
2011464
3
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hit paper breakdown →
2013381
4 2010345
5
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial
Hit paper breakdown →
2015294
6 2015277
7 1998249
8 2009195
9 2008190
10 2008183
11 2006171
12 1999165
13 2015155
14 2011124
15 2011115
16 2010103
17 2007101
18 201397
19 201095
20 201182

About Wilfried Eberhardt

Wilfried Eberhardt is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 243 papers that have together received 7.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (110 papers), Lung Cancer Diagnosis and Treatment (71 papers), Lung Cancer Research Studies (46 papers), Cancer Genomics and Diagnostics (17 papers), Cancer Immunotherapy and Biomarkers (17 papers), Colorectal Cancer Treatments and Studies (16 papers), Cancer Treatment and Pharmacology (15 papers) and Radiomics and Machine Learning in Medical Imaging (13 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (4.5k citations), Oncology (3.1k citations), Cancer Research (709 citations), Radiology, Nuclear Medicine and Imaging (590 citations) and Otorhinolaryngology (94 citations). Wilfried Eberhardt has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Georgios Stamatis, Martin Stuschke, Robert Pirker, Filippo de Marinis, Joachim von Pawel, Christoph Pöttgen, Kenneth J. O’Byrne, Maciej Krzakowski, Thomas Gauler and Rodryg Ramlau. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Lung Cancer, Journal of Thoracic Oncology and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact